Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 29 September 2025

Sec. Pharmacology of Anti-Cancer Drugs

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1682157

This article is part of the Research TopicNovel Anti-Cancer Agents Targeting Tumour Metastasis and Stemness - Volume IIView all 4 articles

Correction: Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation

This article is a correction to:

  1. Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation

    1. Read original article
Daihao Wei,&#x;Daihao Wei1,2†Minyu Li&#x;Minyu Li2†Dawei ChuDawei Chu2Jiandang Shi*Jiandang Shi1*
  • 1Department of Orthopedic, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, Yinchuan, China
  • 2The First School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China

A Correction on
Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation

By Wei D, Li M, Chu D and Shi J (2025). Front. Oncol. 15:1614058. doi: 10.3389/fonc.2025.1614058

There was a mistake in Figure 1 as published. We modified the relevant parameters according to the opinions of the review experts and generated a new Figure 1. The corrected Figure 1 appears below.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Figure 1
Panel A shows a volcano plot displaying gene expression levels with points indicating different gene statuses (down, stable, up). Panel B includes a heatmap and density plot showing distribution data, with colored density gradients and group distinctions. Panel C is a Venn diagram illustrating intersections among DEGs, drug genes, and disease genes, with overlap counts and percentages labeled.

Figure 1. Screening of candidate targets. (A) Volcano plots of 1954 DEGs between the OS and control groups; (B) Heatmap of expression of 1954 DEGs between OS and control groups; (C) The Venn diagram showing 37 targets corresponding to osteosarcoma.

Keywords: solasonine, osteosarcoma, network pharmacology, transcriptomics, experimental validation

Citation: Wei D, Li M, Chu D and Shi J (2025) Correction: Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation. Front. Oncol. 15:1682157. doi: 10.3389/fonc.2025.1682157

Received: 08 August 2025; Accepted: 24 September 2025;
Published: 29 September 2025.

Edited and reviewed by:

Bo Wang, Zhengzhou University, China

Copyright © 2025 Wei, Li, Chu and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jiandang Shi, c2hpX2ppYW5kYW5nQG54bXUuZWR1LmNu

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.